NEW YORK, Oct. 30 (GenomeWeb News) - Amersham PLC has signed an expanded license agreement to Oxford Gene Technologies DNA microarray patents, the company said today.
Oxford Gene Technology is the organization set up to manage the early microarray patents and other intellectual property related to inventions by Oxford University professor Edwin Southern.
The new license gives Amersham the rights to OGT's sequence variation patents, as well as patents the relate to analysis of polynucleotide sequences. The license also gives Amersham the right to sublicense the technology.
The expanded agreement comes in the wake of General Electric's announcement Oct. 10 that it was in the process of acquiring Amersham-a deal that the parties said was partly predicated on the capability of combining the companies' technologies in the nascent area of personalized medicine. (See article in Bioarray News, 10-15-03)
This licensing deal is a move to facilitate the entry of Amersham's CodeLink microarray technology into the personalized medicine arena, particularly in clinical diagnostics, the company said.
"This relationship with OGT will greatly strengthen our CodeLink bioarray platform and will help position CodeLink as the most advanced technology within the scientific community to enable both research and clinical diagnostic applications. Our ability to sublicense this technology will also enable Amersham to make key partnership decisions, especially in the clinical diagnostic field," William Castell, Chief Executive Amersham, said in a statement. "This agreement now paves the way for Amersham to expand the CodeLink product family and to develop CodeLink as a clinical diagnostic platform."
OGT is meanwhile engaged in lawsuits with a variety of other companies in the microarray arena over its patent estate. For more information, see the current issue of BioArray News.